HBIO - Harvard Bioscience, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

HBIO

HARVARD BIOSCIENCE, INC.

NASDAQ

$7.93

▲ UP 0.38% (0.03)

KEY STATISTICS

Market Cap$35.77 M

52w High$9.40

52w Low$3.80

Dividend Yield—

Frequency—

P/E-22.03

Volume20.64K

Shares Out.4.51M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

John Duke

COMPENSATION 2026

Salary$336,923

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$18,900

Total$355,823

ABOUT

SECTOR

Healthcare

WENT PUBLIC

December 7, 2000

METHOD OF GOING PUBLIC

N/A

FULL TIME EMPLOYEES

328

PRICE TARGET

Target High$6.00

Target Low$6.00

Target Median$6.00

Target Consensus$6.00

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.$21.80M

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2026-03-16	Reverse	1:10
2013-11-04	Forward	1319:1000

PRICE

$7.93 ▲ UP 0.38% (+$0.03)

OVERLAYS

About Harvard Bioscience, Inc.

https://www.harvardbioscience.com ↗

Harvard Bioscience develops and sells research, pre-clinical, and scientific instruments and services globally for drug discovery, cellular analysis, and laboratory research across academia, biotech, and pharma.

INDUSTRY

Medical - Instruments & Supplies

A PRODUCT HARVARD BIOSCIENCE, INC. IS KNOWN FOR

SoHo™ Implantable Telemetry Platform

Harvard Bioscience's DSI SoHo™ Implantable Telemetry platform enables continuous, high-quality monitoring of physiological data in freely moving small lab animals, enhancing preclinical research and animal welfare.

COMPETITORS

COMPETITOR

Revenue by Products

Icon	PRODUCT	Q3-2025	Q4-2025	Q1-2026	Q2-2026
	Instruments Equipment Software and Accessories	$18.58M	$21.64M ▲	$18.57M ▼	$20.3M ▲
	Service Maintenance and Warranty Contracts	$2.01M	$2.1M ▲	$2.19M ▲	$2.42M ▲

Revenue by Geography

REGION	Q3-2025	Q4-2025	Q1-2026	Q2-2026
UNITED STATES	$9.25M	$10.23M ▲	$8.8M ▼	$10.5M ▲
EMEA	$6.61M	$7.48M ▲	$6.47M ▼	$6.78M ▲
CHINA	$2.15M	$3.64M ▲	$2.81M ▼	$3.08M ▲
Asia Other	$1.4M	$1.59M ▲	$1.82M ▲	$1.49M ▼
Americas other	$1.19M	$791K ▼	$847K ▲	$878K ▲